RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer
Open Access
- 15 July 2013
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 2 (7) , e55
Abstract
The transcription coactivator Yes-associated protein 1 (YAP1) is regulated by the Hippo tumor suppressor pathway. However, the role of YAP1 in thyroid cancer, which is frequently associated with the BRAFV600E mutation, remains unknown. This study aimed to investigate the role of YAP1 in thyroid cancer. YAP1 was overexpressed in papillary (PTC) and anaplastic thyroid cancer, and nuclear YAP1 was more frequently detected in BRAFV600E (+) PTC. In the thyroid cancer cell lines TPC-1 and HTH7, which do not have the BRAFV600E mutation, YAP1 was cytosolic and inactive at high cell densities. In contrast, YAP1 was retained in the nucleus and its target genes were expressed in the thyroid cancer cells 8505C and K1, which harbor the BRAFV600E mutation, regardless of cell density. Furthermore, the nuclear activation of YAP1 in 8505C was not inhibited by RAF or MEK inhibitor. In vitro experiments, YAP1 silencing or overexpression affected migratory capacities of 8505C and TPC-1 cells. YAP1 knockdown resulted in marked decrease of tumor volume, invasion and distant metastasis in orthotopic tumor xenograft mouse models using the 8505C thyroid cancer cell line. Taken together, YAP1 is involved in the tumor progression of thyroid cancer and YAP1-mediated effects might not be affected by the currently used RAF kinase inhibitors.Keywords
This publication has 60 references indexed in Scilit:
- Faculty Opinions recommendation of High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.2013
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid MalignanciesThe Journal of Clinical Endocrinology & Metabolism, 2011
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Clinical implications of BRAF mutation in thyroid carcinomaTrends in Endocrinology & Metabolism, 2008
- Pathogenetic mechanisms in thyroid follicular-cell neoplasiaNature Reviews Cancer, 2006
- BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2003
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI: Journal of the National Cancer Institute, 2003
- Mutations of the BRAF gene in human cancerNature, 2002